More Than 70 Years of Exceptional Service and Care
As a nationally recognized program, we are at the forefront of prevention, treatment and research for a full spectrum of benign blood disorders, including thrombosis and sickle cell disease. Our expertise spans comprehensive diagnostics, targeted therapies and leading-edge clinical trials that shape the future of hematologic care.
With one of the largest thrombosis prevention and treatment programs and sickle cell clinics in the nation, we possess expertise that continues to drive innovation in patient care, education and research. Home to the first Sickle Cell Center and Research Laboratory in the U.S., we have been driving innovation in research, education and clinical care for blood disorders for more than 70 years. We are one of the few gene-therapy-certified treatment centers for sickle cell disease in the U.S. and are one of the nation’s premier destinations for clotting disorders.
Our research spans from understanding blood disorder biology and genetics to improving treatment options like stem cell therapy and immune modulation. We contribute to national studies through organizations such as the National Institutes of Health, American Society of Hematology (ASH), and the American Thrombosis and Hemostasis Network (ATHN), which help improve patient care. Our work has advanced knowledge in areas like anticoagulation guidelines for COVID-19 and the diagnosis and treatment of Evans syndrome.
Our Team
Montefiore Einstein Hematology (Blood Disorders) brings together world-class hematologists, oncologists and research scientists who are dedicated to improving patient outcomes. Our specialists pioneer advancements in hematology, lead groundbreaking clinical trials and provide individualized treatment plans tailored to each patient’s needs.
